Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcers

被引：22

作者：

Morgner, Andrea ^{[1
]}

Miehlke, Stephen ^{[1
]}

Labenz, Joachim ^{[1
]}

机构：

[1] Univ Essen Gesamthsch, Fac Med, Essen, Germany

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2007年 / 8卷 / 07期

关键词：

dyspeptic symptoms; esomeprazole; gastrointestinal toxicity; NSAID; NSAID-induced ulcers;

D O I：

10.1517/14656566.8.7.975

中图分类号：

R9 [药学];

学科分类号：

1007 [药学];

摘要：

Non-steroidal anti-inflammatory drugs (NSAIDs) represent one of the most widely used drug classes. However, many patients complain of dyspeptic symptoms impairing their quality of life: similar to 20% of patients taking NSAIDs show endoscopic ulcers with or without symptoms, and up to 2% of chronic NSAID users will develop serious complications each year, such as bleeding or perforation, which are the cause of death in many patients. Coprescription of a proton pump inhibitor is one established option for the healing and prevention of NSAID-associated lesions of the upper gastrointestinal tract in patients at risk. Recent studies evaluated the clinical efficacy of esomeprazole in the management of gastrointestinal problems associated with the intake of selective and non-selective NSAIDs and aspirin.

引用

页码：975 / 988

页数：14

共 100 条

[1]

Äbelö A, 2000, DRUG METAB DISPOS, V28, P966

[2]

Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole [J].